On April 23, 2025 OncoHost, a technology company transforming the approach to precision medicine for improved cancer patient outcomes, reported its acceptance to present a scientific poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25–30, 2025, in Chicago, IL (Press release, OncoHost, APR 23, 2025, View Source [SID1234652072]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors," investigates the proteins involved in the PROphetNSCLC model. PROphetNSCLC serves as a treatment guidance tool for patients with advanced stage non-small cell lung cancer (NSCLC). The study is the result of an international collaboration between academic institutions and leading cancer centers including The Ohio State University, UC Davis, Baylor University Medical Center, Roswell Park Comprehensive Cancer Center, and others.
"This research provides a deeper understanding of the biological underpinnings driving resistance to immunotherapy in NSCLC," said Dr. Michal Harel, Director of Science and Innovation at OncoHost and lead author of the study. "Our analysis of resistance-associated proteins (RAPs) identifies key proteomic signatures that not only explain clinical outcomes but can also help stratify patients and identify new therapeutic targets."
PROphetNSCLC is based on 388 plasma proteins, collectively termed RAPs. The study uncovered five distinct expression patterns across healthy individuals, NSCLC patients with clinical benefit (CB), and those with no clinical benefit (NCB) from immunotherapy. These patterns revealed mechanistic insights into treatment resistance that can be monitored in the plasma, highlighting processes such as angiogenesis, immune modulation, chemoresistance, and cell proliferation. In addition, the findings shows that 17.5% of the RAPs identified could be targeted with existing or investigational drugs. These findings suggest that RAPs can serve as a pool of novel targets for intervention, further strengthening the potential clinical significance of these RAPs.
"Being selected to present at AACR (Free AACR Whitepaper) reinforces the scientific and clinical relevance of our work," said Ofer Sharon, MD, CEO of OncoHost. "We are moving beyond predictive diagnostics into an era where understanding the ‘why’ behind treatment resistance is critical to driving real-world precision medicine. This study brings us closer to realizing the full potential of proteomics in oncology."
Poster Presentation Details
Title: Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors
Session Title: Predictive Biomarkers 3
Poster Board #: 27
Presenter: Michal Harel, PhD, Director of Science and Innovation, OncoHost
Date & Time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CDT